Transformation of Market Access Strategies under the Influence of International Harmonization in Health Technology Assessment

Citation: Ivan Metelkin, Nikolay Grechko, "Transformation of Market Access Strategies under the Influence of International Harmonization in Health Technology Assessment", Universal Library of Business and Economics, Volume 02, Issue 03.

Copyright: This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

By 2018, health technology assessment (HTA) had become a central determinant of reimbursement and patient access in most mature pharmaceutical markets, while differences in national assessment methods continued to create substantial evidence and planning burdens for manufacturers. At the same time, European cooperation was moving from voluntary methodological coordination toward a more institutionalized model: EUnetHTA had developed common assessment tools and joint relative-effectiveness work, and on 31 January 2018 the European Commission published proposal COM(2018) 51 for strengthened EU cooperation on HTA. This study examines how that emerging harmonization trajectory was likely to transform pharmaceutical market access strategy as it could reasonably be assessed at the end of March 2018. A structured comparative analysis was conducted for six HTA systems, namely NICE (United Kingdom), CADTH (Canada), G-BA/IQWiG (Germany), HAS (France), Zorginstituut Nederland (the Netherlands), and PBAC (Australia), together with a targeted analysis of EUnetHTA, EMA–EUnetHTA and European Commission documents published from 2014 through March 2018. The analysis identifies substantial convergence in the structure of clinical evidence assessment, especially around population, comparator, patient-relevant outcomes, systematic evidence synthesis and transparency, but persistent divergence in economic evaluation, comparator interpretation, decision rules, pricing mechanisms and the use of real-world evidence. The central strategic implication is that harmonization should not be treated as the creation of a single market-access dossier. Rather, it creates a transferable clinical evidence core that must be designed early and then connected to country-specific economic and reimbursement modules. To operationalize this approach, the paper proposes an Integrated Harmonized Market Access Strategy (IHMAS) framework linking evidence architecture, regulatory–HTA alignment, national economic adaptation, real-world evidence planning, early dialogue, budget impact, value communication and pricing scenarios.

Keywords: Health Technology Assessment, Market Access, HTA Harmonization, EU HTA Regulation, Joint Clinical Assessment, Pharmacoeconomics, Cost-Effectiveness Analysis, Real-World Evidence, ICER, Reimbursement Strategy.

https://doi.org/10.70315/uloap.ulbec.2025.0203028